Vistagen Stock at 63 Cents: The June Trial Readout Traders Are Watching
Vistagen Therapeutics shares were little changed before the regular Nasdaq open on Monday, quoted around $0.63, as investors looked past a quiet weekend and toward a trial-data window that could set the next move in the small biotech stock. U.S. equity markets were on a normal schedule; Nasdaq’s 2026 calendar lists the next June closure as Juneteenth on June 19. The timing matters. Vistagen, valued at about $26.6 million, is heading into June with its lead anxiety drug still carrying most of the equity story, while the SPDR S&P Biotech ETF, a broad gauge of biotech risk appetite, was modestly firmer before the open.